SerpinE2 promotes multiple cell proliferation and drug resistance in osteosarcoma

Mao,Minzhi; Wang,Wanchun

doi:10.3892/mmr.2016.5316

SerpinE2 promotes multiple cell proliferation and drug resistance in osteosarcoma

Authors:
- Minzhi Mao
- Wanchun Wang
View Affiliations

Affiliations: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
Published online on: May 19, 2016 https://doi.org/10.3892/mmr.2016.5316
Pages: 881-887

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SerpinE2 is a member of the Serpins family, which could inhibit serine protease and promote tumor progression, particularly in tumor metastasis. However, at present, its role in the progression of osteosarcoma has not been determined. The present study analyzed the expression profiles of SerpinE2 in cancer tissues, including tissues from osteosarcoma of different stages. Higher expression of SerpinE2 was shown in osteosarcoma tissues, particularly in tissue from patients with metastasis and a tumor-node-metastasis stage II‑III. Following chemotherapy, the SerpinE2 expression levels were shown to be higher than those at diagnosis. Cell proliferation and colony formation were increased after transfection with SerpinE2 over‑expression vector. Additionally, drug resistance to bortezomib and doxorubicin treatment following SerpinE2 transfection was analyzed. MG‑63 and SAOS‑2 cells showed less sensitivity following transfection with SerpinE2. The cell cycle‑related genes, cyclin‑dependent kinase (CDK)4 and cyclin D1 were positively correlated with SerpinE2 expression in patient‑derived tissue and in osteosarcoma cells. Finally, the high expression of SerpinE2 contributes to poor survival rates in patients with osteosarcoma. In conclusion, high expression of SerpinE2 in osteosarcoma stimulates cell proliferation, promotes drug‑resistance, and results in poor survival by regulating CDK4 and cyclin D1. Thus, SerpinE2 could be a potential target for treatment of patients with osteosarcoma.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol. 11:670–678. 2010. View Article : Google Scholar : PubMed/NCBI
3	Yang J and Zhang W: New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406. 2013. View Article : Google Scholar : PubMed/NCBI
4	Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, et al: The serpins are an expanding superfamily of structurally similar but funtionally diverse proteins: Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem. 276:33293–33296. 2001. View Article : Google Scholar : PubMed/NCBI
5	Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E and Massagué J: Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 156:1002–1016. 2014. View Article : Google Scholar : PubMed/NCBI
6	Paik PK, Shen R, Won H, Rekhtman N, Wang L, Sima CS, Arora A, Seshan V, Ladanyi M, Berger MF and Kris MG: Next-Generation sequencing of stage IV squamous cell lung cancers reveals an association of PI3K aberrations and evidence of clonal heterogeneity in patients with brain metastases. Cancer Discov. 5:610–621. 2015. View Article : Google Scholar : PubMed/NCBI
7	Shiiba M, Nomura H, Shinozuka K, Saito K, Kouzu Y, Kasamatsu A, Sakamoto Y, Murano A, Ono K, Ogawara K, et al: Down-regulated expression of SERPIN genes located on chromosome 18q21 in oral squamous cell carcinomas. Oncol Rep. 24:241–249. 2010. View Article : Google Scholar : PubMed/NCBI
8	Li Z, Liu Q, Song M, Zheng Y, Nan P, Cao Y, Chen G, Li Y and Zhong Y: Detecting correlation between sequence and expression divergences in a comparative analysis of human serpin genes. Biosystems. 82:226–234. 2005. View Article : Google Scholar : PubMed/NCBI
9	Erler JT: Cancer: Disabling defences in the brain. Nature. 508:46–47. 2014. View Article : Google Scholar : PubMed/NCBI
10	Medress Z and Hayden Gephart M: Molecular and genetic predictors of breast-to-brain metastasis: Review and case presentation. Cureus. 7:e2462015.PubMed/NCBI
11	Nagahara A, Nakayama M, Oka D, Tsuchiya M, Kawashima A, Mukai M, Nakai Y, Takayama H, Nishimura K, Jo Y, et al: SERPINE2 is a possible candidate promotor for lymph node metastasis in testicular cancer. Biochem Biophys Res Commun. 391:1641–1646. 2010. View Article : Google Scholar
12	Lee RK, Fan CC, Hwu YM, Lu CH, Lin MH, Chen YJ and Li SH: SERPINE2, an inhibitor of plasminogen activators, is highly expressed in the human endometrium during the secretory phase. Reprod Biol Endocrinol. 9:382011. View Article : Google Scholar : PubMed/NCBI
13	Demeo DL, Mariani TJ, Lange C, Srisuma S, Litonjua AA, Celedon JC, Lake SL, Reilly JJ, Chapman HA, Mecham BH, et al: The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am J Hum Genet. 78:253–264. 2006. View Article : Google Scholar :
14	Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, Leder G, Adler G and Gress TM: SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 63:4945–4951. 2003.PubMed/NCBI
15	Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989–997. 2008. View Article : Google Scholar : PubMed/NCBI
16	Bergeron S, Lemieux E, Durand V, Cagnol S, Carrier JC, Lussier JG, Boucher MJ and Rivard N: The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Mol Cancer. 9:2712010. View Article : Google Scholar : PubMed/NCBI
17	Gao S, Krogdahl A, Sørensen JA, Kousted TM, Dabelsteen E and Andreasen PA: Overexpression of protease nexin-1 mRNA and protein in oral squamous cell carcinomas. Oral Oncol. 44:309–313. 2008. View Article : Google Scholar
18	Neesse A, Wagner M, Ellenrieder V, Bachem M, Gress TM and Buchholz M: Pancreatic stellate cells potentiate proinvasive effects of SERPINE2 expression in pancreatic cancer xenograft tumors. Pancreatology. 7:380–385. 2007. View Article : Google Scholar : PubMed/NCBI
19	Schajowicz F, Sissons HA and Sobin LH: The World Health Organization's histologic classification of bone tumors. Cancer. 75:1208–1214. 1995. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Watanabe R, Iida S, Shimizu Y, Nagata S and Fukunaga R: SEI family of nuclear factors regulates p53-dependent transcriptional activation. Genes Cells. 10:851–860. 2005. View Article : Google Scholar
22	Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C and Krönke M: NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood. 109:3982–3988. 2007. View Article : Google Scholar
23	Wang K, Wang B, Xing AY, Xu KS, Li GX and Yu ZH: Prognostic significance of SERPINE2 in gastric cancer and its biological function in SGC7901 cells. J Cancer Res Clin Oncol. 141:805–812. 2015. View Article : Google Scholar
24	Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S and van de Vijver MJ: Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 23:3331–3342. 2005. View Article : Google Scholar : PubMed/NCBI
25	van't Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar
26	Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, et al: Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 351:533–542. 2004. View Article : Google Scholar : PubMed/NCBI
27	Vaillant C, Valdivieso P, Nuciforo S, Kool M, Schwarzentruber-Schauerte A, Méreau H, Cabuy E, Lobrinus JA, Pfister S, Zuniga A, et al: Serpine2/PN-1 is required for proliferative expansion of pre-neoplastic lesions and malignant progression to medulloblastoma. PLoS One. 10:e01248702015. View Article : Google Scholar : PubMed/NCBI